Ocular Therapeutix (NASDAQ:OCUL) Research Coverage Started at Piper Sandler

Piper Sandler began coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research report sent to investors on Friday, StockNewsAPI reports. The brokerage issued an overweight rating and a $15.00 price objective on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. JMP Securities lowered their […]

Leave a Reply

Your email address will not be published.

Previous post BE Semiconductor Industries (OTCMKTS:BESIY) Short Interest Up 11.1% in May
Next post Stitch Fix (NASDAQ:SFIX) Rating Reiterated by Telsey Advisory Group